[go: up one dir, main page]

WO2004039321A2 - Therapie associee agoniste nicotinique/agoniste d1 pour le traitement de la maladie d'alzheimer - Google Patents

Therapie associee agoniste nicotinique/agoniste d1 pour le traitement de la maladie d'alzheimer Download PDF

Info

Publication number
WO2004039321A2
WO2004039321A2 PCT/US2003/033729 US0333729W WO2004039321A2 WO 2004039321 A2 WO2004039321 A2 WO 2004039321A2 US 0333729 W US0333729 W US 0333729W WO 2004039321 A2 WO2004039321 A2 WO 2004039321A2
Authority
WO
WIPO (PCT)
Prior art keywords
alpha
nicotinic
agonist
disease
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/033729
Other languages
English (en)
Other versions
WO2004039321A8 (fr
Inventor
Graham V. Williams
Stacy A. Castner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MIICRO Inc
Micro Inc
Original Assignee
MIICRO Inc
Micro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MIICRO Inc, Micro Inc filed Critical MIICRO Inc
Priority to AU2003284898A priority Critical patent/AU2003284898A1/en
Publication of WO2004039321A2 publication Critical patent/WO2004039321A2/fr
Anticipated expiration legal-status Critical
Publication of WO2004039321A8 publication Critical patent/WO2004039321A8/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Definitions

  • Another embodiment of the invention provides a method of treating Alzheimer's disease in a subject comprising administration to the subject a combination comprising an alpha-7-nicotinic agonist and a Dl receptor agonist, wherein the alpha-7-nicotinic agonist and the Dl receptor agonist together comprise a therapeutically effective amount of the alpha-7-nicotinic agonist and the Dl receptor agonist.
  • the administration of each of the alpha-7-nicotinic agonist and the Dl receptor agonist can occur sequentially within about 24 hours, about 12 hours, about 6 hours, about 3 hours, and about 1 hour.
  • the administration of each of the alpha-7-nicotinic agonist and the Dl receptor agonist can occur substantially concomitantly.
  • compositions of the invention can be delivered to a subject by systemic administration.
  • Systemic administration is in vivo systemic absorption or accumulation of drugs in the blood stream followed by distribution throughout the entire body. Administration routes that can lead to systemic absorption include, without limitation: intravenous, subcutaneous, intraperitoneal, inhalation, transdermal, oral, intrapulmonary and intramuscular.
  • Formulations for oral use can also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • water or an oil medium for example peanut oil, liquid paraffin or olive oil.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne des thérapies associées pour le traitement de la maladie d'Alzheimer. Selon un de ses aspects, l'invention concerne une thérapie combinatoire pour des sujets chez lesquelles la maladie d'Alzheimer a été diagnostiquée, qui consiste en une combinaison optimale d'un de plusieurs agonistes nicotiniques alpha-7 et d'un ou de plusieurs agonistes du récepteur D1.
PCT/US2003/033729 2002-10-29 2003-10-24 Therapie associee agoniste nicotinique/agoniste d1 pour le traitement de la maladie d'alzheimer Ceased WO2004039321A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003284898A AU2003284898A1 (en) 2002-10-29 2003-10-24 Combinative nicotinic/d1 agonism therapy for the treatment of alzheimer's disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42204702P 2002-10-29 2002-10-29
US60/422,047 2002-10-29

Publications (2)

Publication Number Publication Date
WO2004039321A2 true WO2004039321A2 (fr) 2004-05-13
WO2004039321A8 WO2004039321A8 (fr) 2005-05-26

Family

ID=32230314

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/033729 Ceased WO2004039321A2 (fr) 2002-10-29 2003-10-24 Therapie associee agoniste nicotinique/agoniste d1 pour le traitement de la maladie d'alzheimer

Country Status (2)

Country Link
AU (1) AU2003284898A1 (fr)
WO (1) WO2004039321A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006048294A1 (fr) * 2004-11-05 2006-05-11 Novartis Ag Combinaisons d'agonistes du recepteur nicotinique alpha 7 de l'acetylcholine
US7713976B2 (en) 2005-12-16 2010-05-11 Novartis Ag [(1H-indol-5-yl)-heteroaryloxy]-1-aza-bicylco[3.3.1]nonanes as cholinergic ligands of the n-AChR for the treatment of psychotic and neurodegenerative disorders
US7713977B2 (en) 2005-12-16 2010-05-11 Novartis Ag (1-aza-bicyclo[3.3.1]non-4-yl)-[5-(1H-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenerative disorders
US8173667B2 (en) 2005-10-21 2012-05-08 Novartis Ag 1-aza-bicycloalkyl derivatives
US8236803B2 (en) 2002-09-04 2012-08-07 Novartis Ag Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonists
US8609662B2 (en) 2004-07-14 2013-12-17 Novartis Ag 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha. 7-nachr ligands for the treatment of CNS diseases
US8884017B2 (en) 2001-12-27 2014-11-11 Bayer Intellectual Property Gmbh 2-heteroarylcarboxylic acid amides
US8933090B2 (en) 2004-06-18 2015-01-13 Novartis Ag 1-aza-bicyclo[3.3.1]nonanes

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101698250B1 (ko) 2010-05-17 2017-01-19 포럼 파마슈티칼즈 인크. (R)-7-클로로-N-(퀴누클리딘-3-일)벤조[b]티오펜-2-카르복사미드 히드로클로리드 모노히드레이트의 결정질 형태
RU2635522C2 (ru) 2012-05-08 2017-11-13 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8884017B2 (en) 2001-12-27 2014-11-11 Bayer Intellectual Property Gmbh 2-heteroarylcarboxylic acid amides
US9567343B2 (en) 2002-09-04 2017-02-14 Novartis Ag Aza-bicyloalkyl ethers and their use as alpha7-nachr agonists
US9849117B2 (en) 2002-09-04 2017-12-26 Novartis Ag Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists
US9012451B2 (en) 2002-09-04 2015-04-21 Novartis Ag Aza-bicycloalkyl ethers and their use as ALPHA7-nachr agonists
US8236803B2 (en) 2002-09-04 2012-08-07 Novartis Ag Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonists
US9475811B2 (en) 2004-06-18 2016-10-25 Novartis Ag 1-aza-bicyclo[3.3.1]nonanes
US8933090B2 (en) 2004-06-18 2015-01-13 Novartis Ag 1-aza-bicyclo[3.3.1]nonanes
US9657010B2 (en) 2004-07-14 2017-05-23 Novartis Ag Substituted quinuclidines as alpha 7-nicotinic acetylcholine receptor activity modulators
US8609662B2 (en) 2004-07-14 2013-12-17 Novartis Ag 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha. 7-nachr ligands for the treatment of CNS diseases
EP2135609A1 (fr) * 2004-11-05 2009-12-23 Novartis AG Combinaisons d'agonistes du recepteur nicotine-acetylcholine-alpha-7
EP2332537A1 (fr) * 2004-11-05 2011-06-15 Novartis AG Combinaisons d'agonistes du recepteur nicotine-acetylcholine-alpha-7
WO2006048294A1 (fr) * 2004-11-05 2006-05-11 Novartis Ag Combinaisons d'agonistes du recepteur nicotinique alpha 7 de l'acetylcholine
JP2008518896A (ja) * 2004-11-05 2008-06-05 ノバルティス アクチエンゲゼルシャフト ニコチン性アセチルコリンα７受容体アンタゴニストの組合せ剤
US8173667B2 (en) 2005-10-21 2012-05-08 Novartis Ag 1-aza-bicycloalkyl derivatives
US8637517B2 (en) 2005-12-16 2014-01-28 Novartis Ag Organic compounds
US9206181B2 (en) 2005-12-16 2015-12-08 Novartis Ag 1-aza-bicyclo[3.3.1] non-4-yl)-[5-(1H-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-AChR for the treatment of psychotic and neurodegenerative disorders
US8759346B2 (en) 2005-12-16 2014-06-24 Novartis Ag Organic compounds
US8048885B2 (en) 2005-12-16 2011-11-01 Novartis Ag Organic compounds
US7713977B2 (en) 2005-12-16 2010-05-11 Novartis Ag (1-aza-bicyclo[3.3.1]non-4-yl)-[5-(1H-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenerative disorders
US7713976B2 (en) 2005-12-16 2010-05-11 Novartis Ag [(1H-indol-5-yl)-heteroaryloxy]-1-aza-bicylco[3.3.1]nonanes as cholinergic ligands of the n-AChR for the treatment of psychotic and neurodegenerative disorders

Also Published As

Publication number Publication date
AU2003284898A1 (en) 2004-05-25
WO2004039321A8 (fr) 2005-05-26

Similar Documents

Publication Publication Date Title
KR101660555B1 (ko) Ｓ１ｐ 수용체 효능제의 투여 요법
CA2909160C (fr) Formulations d'oxabicycloheptanes et d'oxabicycloheptenes
US20040242634A1 (en) Methods for treating prion diseases
WO2004039322A2 (fr) Nouvelle polytherapie pour la schizophrenie, fondee sur une cognition amelioree : blocage de 5-ht-2a/d2 avec blocage auxiliaire du recaptage da prefrontal
CA2781436C (fr) Analogues de l'acide arachidonique et procedes pour un traitement analgesique l'utilisant
US20220340650A1 (en) Combination therapy with cgrp antagonists
JP2009292850A (ja) 抗癌治療
BR112020019325A2 (pt) Método de tratamento de doença fibrótica
US20100222376A1 (en) Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders
US8541433B2 (en) Combination comprising macitentan and paclitaxel for treating multi-drug resistant ovarian cancer
US20200171014A1 (en) Oxybutynin-xanomeline transdermal therapeutic system combinations
WO2004039321A2 (fr) Therapie associee agoniste nicotinique/agoniste d1 pour le traitement de la maladie d'alzheimer
WO2010028134A2 (fr) Traitement de troubles neurologiques à l'aide d'huperzine
US20080161389A1 (en) Method of treating ocular hypertension and intestinal disorders by using dianhydrohexite mononitrate derivatives
Strumper et al. Antidepressants as long-acting local anesthetics
US20100310674A1 (en) Novel composition for treating the side effects of anticancer treatments
CA2860473A1 (fr) Therapie combinee destinee au traitement du cancer
JP2010526073A (ja) 癌または前癌性症状およびその他の症状の治療のためのジヒドロピリジン誘導体
CN112912076A (zh) 氨基甲酸酯化合物用于预防、缓解或治疗糖尿病性周围神经病变或化疗诱发性周围神经病变的用途
CN100402029C (zh) 包含埃坡霉素衍生物和烷化剂的组合
AU5430899A (en) Drug targeting
JP2015227288A (ja) けいれん重積発作の治療用医薬組成物
JP2002363076A (ja) フマギロール誘導体を用いる腫瘍の治療方法
US20240293435A1 (en) Methods and Compositions for Treating Human Disorders Using D-Cycloserine and a Psychedelic Agent
EP1632229A1 (fr) Médicaments pour le traitement des maladies des voies urinaires contenant des anticholinergiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 20/2004 UNDER (71) THE NAME SHOULD READ "MIICRO, INC."

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP